Led by one of the most experienced Proton Therapy and Oncology teams in the world, the Proton Therapy Clinical Indications course aims to provide Physicians, Radiation Oncologists, Medical Oncologists, Haematologist Oncologists, Neurologists, Surgeons, and others interested in the clinical side of Proton Therapy with a comprehensive hands-on experience in the clinical practice and application of Proton Therapy. Attendees will get hands-on with a special demo, that shows the treatment from start to finish. 

The course will be taught by SAH Global’s Proton Therapy physicians Dr. Allan Thornton and Dr. Andrew Chang.

• Assist attendees in understanding the clinical indications for proton therapy
• Attendees will understand the treatment process for proton therapy

Dr. Allan Thornton is a renowned Radiation Oncologist who is considered to be one of the best proton therapy physicians in the world. He has more than 27 years of experience using Proton Therapy to fight a range of cancers and his expertise on complex cases is sought by hospitals and physicians around the world. Dr. Thornton conducts ongoing research and development in the field of Proton Therapy, and his work is considered to be some of the most influential in the field.

Dr. Andrew L. Chang is a highly specialized Radiation Oncologist belonging to a narrow subset of extensively trained specialists in the United States. He is one of only five Radiation Oncologists in the United States who specialize in Pediatric Proton Therapy. He trained at the first clinical proton radiation therapy center in the world at Loma Linda University Medical Center and completed extensive research in the field of proton therapy for pediatric patients, stereotactic radiosurgery, and pediatric Chordomas.

Proton Therapy is a breakthrough in the search for gentler cancer treatments for infants and children. Proton Therapy aggressively treats the cancer while substantially reducing side effects that could impact the child’s development and quality of life. This advanced cancer therapy has been proven to protect vital organs, important tissues, nerves, and glands during treatment, while also decreasing the estimated risk of secondary malignancies. 

• Assist attendees in understanding the clinical benefits for proton therapy
• Attendees will understand the treatment process for proton therapy

Dr. Allan Thornton is a renowned Radiation Oncologist who is considered to be one of the best proton therapy physicians in the world. He has more than 27 years of experience using Proton Therapy to fight a range of cancers and his expertise on complex cases is sought by hospitals and physicians around the world. Dr. Thornton conducts ongoing research and development in the field of Proton Therapy, and his work is considered to be some of the most influential in the field.

Dr. Andrew L. Chang is a highly specialized Radiation Oncologist belonging to a narrow subset of extensively trained specialists in the United States. He is one of only five Radiation Oncologists in the United States who specialize in Pediatric Proton Therapy. He trained at the first clinical proton radiation therapy center in the world at Loma Linda University Medical Center and completed extensive research in the field of proton therapy for pediatric patients, stereotactic radiosurgery, and pediatric Chordomas.

Proton Therapy delivers a highly targeted, extremely precise dose of radiation that can reach and treat tumors located in the tiny, narrow areas of the head and neck, brain and spine.

Proton Therapy can deliver higher, more effective doses of radiation to eliminate the tumor, while protecting the patient against adverse outcomes like neurological damage and dysfunction. In addition to treating malignancies, proton therapy may even be effective in treating benign tumors that pose their own health risks.

• Assist attendees in understanding the clinical benefits for proton therapy
• Attendees will understand the treatment process for proton therapy

Dr. Allan Thornton is a renowned Radiation Oncologist who is considered to be one of the best proton therapy physicians in the world. He has more than 27 years of experience using Proton Therapy to fight a range of cancers and his expertise on complex cases is sought by hospitals and physicians around the world. Dr. Thornton conducts ongoing research and development in the field of Proton Therapy, and his work is considered to be some of the most influential in the field.

Dr. Andrew L. Chang is a highly specialized Radiation Oncologist belonging to a narrow subset of extensively trained specialists in the United States. He is one of only five Radiation Oncologists in the United States who specialize in Pediatric Proton Therapy. He trained at the first clinical proton radiation therapy center in the world at Loma Linda University Medical Center and completed extensive research in the field of proton therapy for pediatric patients, stereotactic radiosurgery, and pediatric Chordomas.

Proton Therapy is very beneficial for patients with cancer that occurs near vital organs. It can be precisely and narrowly targeted specifically on cancerous tumors and tissues, applying intense amounts of radiation only to the affected area. This advanced therapy is most commonly used for localized cancer and tumors that have not
spread, or metastasized, to other distant parts of the body, such as Bone Cancer, Sarcoma, and Lymphoma.

• Assist attendees in understanding the clinical benefits for proton therapy
• Attendees will understand the treatment process for proton therapy

Dr. Allan Thornton is a renowned Radiation Oncologist who is considered to be one of the best proton therapy physicians in the world. He has more than 27 years of experience using Proton Therapy to fight a range of cancers and his expertise on complex cases is sought by hospitals and physicians around the world. Dr. Thornton conducts ongoing research and development in the field of Proton Therapy, and his work is considered to be some of the most influential in the field.

Dr. Andrew L. Chang is a highly specialized Radiation Oncologist belonging to a narrow subset of extensively trained specialists in the United States. He is one of only five Radiation Oncologists in the United States who specialize in Pediatric Proton Therapy. He trained at the first clinical proton radiation therapy center in the world at Loma Linda University Medical Center and completed extensive research in the field of proton therapy for pediatric patients, stereotactic radiosurgery, and pediatric Chordomas.

This module is geared towards radiation oncology medical professions (e.g. Physicians, Physicists, Dosimetrists) who would like to gain an interactive understanding on proton
therapy and its ability to spare healthy tissue while delivering curative dosing. The goal of this educational class is for attendees to express their photon delivery practices and have those compared to proton delivery practices. The class will highlight the benefits of proton therapy delivery and the uniqueness of the beam compared to photons. 

• Attendees will understand general physics principles/fundamentals of proton treatment planning
• Attendees will understand comparisons of planning between Photon and Proton treatments

Mary-Beth Sullivan is a highly skilled radiation therapist with over 25 years of experience in both photon and proton therapy facilities. Previously, a Proton therapy specialist at Harvard Cyclotron Laboratories Mass General Hospital. She is currently engaged with a Proton Therapy center in the U.S. as the Director of Clinical Proton Services.

Trevor Twyford is currently an ABR Certified Medical Physicist and Radiation Safety Officer for Procure Proton Therapy Center in Oklahoma. He originally received his Master’s degree from Columbia University before beginning work at Hampton University's Proton Therapy Center prior to Procure. Mr. Twyford has over seven years of experience in proton therapy and has worked with many vendors, treatment service providers, and treatment planning systems; including XiO, Eclipse, and RayStation.  Mr. Twyford enjoys working on new and emerging technologies and finding ways to incorporate them into radiation oncology, and into enhancing the patient care experience.

There is an emerging focus to optimize patient engagement for improved quality and efficiency of care by integrating electronic patient reported outcomes (PROMs) in the
clinical workflow. This session will provide use cases, results and lessons learned for the process of selecting PROMs by utilizing the VisionTree Optimal Care (VTOC) v4.1 platform, which is implemented at over 600 sites globally, including 8 of the top 10 U.S. News and World Report Hospitals such as MD Anderson and UCLA.

• How to use electronic patient reported outcomes measures (PROMs) to deliver quality and cost efficiency 
• How to use PROMs established in the literature for research/registries
• How to identify and set up roles-based form alerts, selecting which questions/answers values should trigger an alert and expected medical team responses

Martin PELLINAT founded VisionTree Software, Inc. in 2003, and serves as its Chief Executive Officer. Mr. Pellinat has over 15 years of experience in the medical and software fields. Mr. Pellinat has held strategic management positions in the fields of sales, marketing and product development at Johnson & Johnson, Boston Scientific Corporation and BrainLAB, Inc.

ECS-Screening developed the first early cancer screening that can detect multiple cancers before symptoms appear. Called DECODE Lab it detects a specific cancer biomarker in the blood called Progastrin. The DECODE Lab screening test presents an innovative and long-sought after solution to early stage cancer detection that is simple, reliable, reproducible, cheap and valid for multiple cancers.

Attendees will gain an understanding of the novel new approach for early detection utilizing the DECODE Lab and how biomarkers play in the early detection of cancer. 

Alexandre PRIEUR, Chief Scientific Officer, ECS Screening, has a PhD in cancerology and worked for twelve years as research scientist in the academic field in leading cancer institutes in Europe. He then joined the biotech field to give more chances to innovative biomedical projects to reach the patients. He has now 5 years’ experience in
R&D management in biotech companies developing projects in cancer field either on therapy or screening.